Zacks: Athersys, Inc. (NASDAQ:ATHX) Given Average Recommendation of “Strong Buy” by Analysts

Share on StockTwits

Athersys, Inc. (NASDAQ:ATHX) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus target price of $11.00 for the company and are anticipating that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Athersys an industry rank of 57 out of 255 based on the ratings given to related companies.

Separately, Dawson James began coverage on shares of Athersys in a research note on Monday, August 26th. They issued a “buy” rating and a $11.00 price target on the stock.

In related news, COO William Lehmann, Jr. sold 30,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $1.44, for a total transaction of $43,200.00. Following the completion of the transaction, the chief operating officer now directly owns 542,196 shares of the company’s stock, valued at $780,762.24. The sale was disclosed in a filing with the SEC, which is available through this link. 15.31% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ATHX. Commonwealth Equity Services LLC increased its position in shares of Athersys by 52.0% during the 2nd quarter. Commonwealth Equity Services LLC now owns 22,795 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 7,795 shares during the last quarter. Envestnet Asset Management Inc. bought a new stake in Athersys in the second quarter worth $42,000. Advisor Group Inc. lifted its position in Athersys by 25,189.0% in the second quarter. Advisor Group Inc. now owns 25,289 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 25,189 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in Athersys during the second quarter worth $52,000. Finally, Cambridge Investment Research Advisors Inc. increased its position in Athersys by 133.2% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 37,550 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 21,450 shares during the last quarter. Institutional investors own 21.37% of the company’s stock.

Athersys stock opened at $1.31 on Friday. Athersys has a 1 year low of $1.20 and a 1 year high of $2.15. The firm’s 50 day moving average price is $1.34 and its 200-day moving average price is $1.47.

Athersys (NASDAQ:ATHX) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.08). The firm had revenue of ($0.36) million during the quarter, compared to analyst estimates of $1.51 million. Athersys had a negative net margin of 458.03% and a negative return on equity of 131.22%. As a group, analysts anticipate that Athersys will post -0.31 earnings per share for the current fiscal year.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Featured Story: What is a resistance level?

Get a free copy of the Zacks research report on Athersys (ATHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.